Wuxi Pharmatech Inc., of Shanghai, said its toxicology facility in Suzhou, China, recently passed a surveillance good laboratory practice inspection by the FDA with no major observations. This was the first such inspection in the facility's five years of operation. The inspection was extensive, lasting five days and included the review of numerous processes and the audit of four studies, the company said.
SHANGHAI – Chia-Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ), of Jiangsu, has taken steps to bring a biosimilar version of Pfizer Inc.'s Xyntha, a recombinant human coagulation factor VIII (rhFVIII), to the clinic and moves a step closer to providing a much-needed, affordable treatment for China's hemophilia A sufferers.
HONG KONG – A large Chinese conglomerate that rose to fame as a maker of the food additive monosodium glutamate, better known as MSG, has taken definitive steps into the biopharmaceutical space, sealing a deal to buying one of the major hepatitis B vaccine (HBV) suppliers in the country for ¥600 million (US$96 million).
SHANGHAI – A new licensing deal is giving Taiwan’s Taigen Biotechnology Co. inroads into the large Russian market just as the parent company’s shares started trading in Taiwan.
HONG KONG – Looking to reach out to more users and drug companies and riding the wave of growth of online information and platforms to facilitate the sharing of information between governments and users, China's drug regulator is now using mobile technology as part of its communications strategy.
Senju Pharmaceutical Co. Ltd., of Osaka, Japan, will pay Alameda, Calif.-based Insite Vision Inc. an undisclosed amount for the right to develop and market ocular antibiotics incorporating Insite's Durasite drug delivery platfom in Japan. The deal includes an up-front license fee, additional development milestones fees and a percentage royalty on net sales.
SHANGHAI – For some pharma executives parachuting into China it may come as a surprise to learn that the best way to get rid of a corrupt employee is to pay them off.
SHANGHAI – Last week the CFDA put out a circular to warn Chinese consumers about the dangers of buying cancer medicines online, in particular drugs that claim to be Iressa (gefitinib) imported from India.
Ruiyi Inc. and the Ihuman Institute forged a research collaboration allowing the upstart educational institution, housed at China's Shanghaitech University, to apply the company's intermembranous conformation antigen presenting system, or iCAPS, technology for the creation of monoclonal antibodies (MAb) that specifically bind to G protein-coupled receptors (GPCR). The goal of the program is to investigate the biological function and structure of GPCRs.
TOKYO – Representatives of various U.S. organizations are urging Japan to reconsider a proposal that would revise reimbursement prices for pharmaceuticals on an annual, rather than a biennial, basis.
RSS